SOLV Quote, Financials, Valuation and Earnings

Milestone Scientific has a net margin of 6.62% compared to Solventum's net margin of -58.13%. Solventum's return on equity of 11.75% beat Milestone Scientific's return on equity of -61.33%.

Solventum has a consensus price target of $80.14, signalling upside risk potential of 12.66%. On the other hand Milestone Scientific has an analysts' consensus of $2.13 which suggests that it could grow by 138.74%. Given that Milestone Scientific has higher upside potential than Solventum, analysts believe Milestone Scientific is more attractive than Solventum.

Solventum has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Milestone Scientific has a beta of 0.934, suggesting its less volatile than the S&P 500 by 6.585%.

Solventum has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Milestone Scientific offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Solventum pays -- of its earnings as a dividend. Milestone Scientific pays out -- of its earnings as a dividend.

Solventum quarterly revenues are $2.1B, which are larger than Milestone Scientific quarterly revenues of $2.5M. Solventum's net income of $137M is higher than Milestone Scientific's net income of -$1.5M. Notably, Solventum's price-to-earnings ratio is 32.94x while Milestone Scientific's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Solventum is 1.49x versus 8.21x for Milestone Scientific. Usually stocks with elevated PS ratios are considered overvalued.

Envista Holdings has a net margin of 6.62% compared to Solventum's net margin of 2.92%. Solventum's return on equity of 11.75% beat Envista Holdings's return on equity of -34.78%.

Solventum has a consensus price target of $80.14, signalling upside risk potential of 12.66%. On the other hand Envista Holdings has an analysts' consensus of $19.13 which suggests that it could grow by 6.67%. Given that Solventum has higher upside potential than Envista Holdings, analysts believe Solventum is more attractive than Envista Holdings.

Solventum has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Envista Holdings has a beta of 0.975, suggesting its less volatile than the S&P 500 by 2.472%.

Solventum has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Envista Holdings offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Solventum pays -- of its earnings as a dividend. Envista Holdings pays out -- of its earnings as a dividend.

Solventum quarterly revenues are $2.1B, which are larger than Envista Holdings quarterly revenues of $616.9M. Solventum's net income of $137M is higher than Envista Holdings's net income of $18M. Notably, Solventum's price-to-earnings ratio is 32.94x while Envista Holdings's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Solventum is 1.49x versus 1.24x for Envista Holdings. Usually stocks with elevated PS ratios are considered overvalued.

Thermo Fisher Scientific has a net margin of 6.62% compared to Solventum's net margin of 14.54%. Solventum's return on equity of 11.75% beat Thermo Fisher Scientific's return on equity of 13.49%.

Solventum has a consensus price target of $80.14, signalling upside risk potential of 12.66%. On the other hand Thermo Fisher Scientific has an analysts' consensus of $570.17 which suggests that it could grow by 40.42%. Given that Thermo Fisher Scientific has higher upside potential than Solventum, analysts believe Thermo Fisher Scientific is more attractive than Solventum.

Solventum has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Thermo Fisher Scientific has a beta of 0.822, suggesting its less volatile than the S&P 500 by 17.823%.

Solventum has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Thermo Fisher Scientific offers a yield of 0.39% to investors and pays a quarterly dividend of $0.43 per share. Solventum pays -- of its earnings as a dividend. Thermo Fisher Scientific pays out 9.2% of its earnings as a dividend. Thermo Fisher Scientific's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Solventum quarterly revenues are $2.1B, which are smaller than Thermo Fisher Scientific quarterly revenues of $10.4B. Solventum's net income of $137M is lower than Thermo Fisher Scientific's net income of $1.5B. Notably, Solventum's price-to-earnings ratio is 32.94x while Thermo Fisher Scientific's PE ratio is 23.82x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Solventum is 1.49x versus 3.62x for Thermo Fisher Scientific. Usually stocks with elevated PS ratios are considered overvalued.

Dentsply Sirona has a net margin of 6.62% compared to Solventum's net margin of 2.28%. Solventum's return on equity of 11.75% beat Dentsply Sirona's return on equity of -35.57%.

Solventum has a consensus price target of $80.14, signalling upside risk potential of 12.66%. On the other hand Dentsply Sirona has an analysts' consensus of $18.14 which suggests that it could grow by 9.29%. Given that Solventum has higher upside potential than Dentsply Sirona, analysts believe Solventum is more attractive than Dentsply Sirona.

Solventum has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Dentsply Sirona has a beta of 0.924, suggesting its less volatile than the S&P 500 by 7.642%.

Solventum has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Dentsply Sirona offers a yield of 3.86% to investors and pays a quarterly dividend of $0.16 per share. Solventum pays -- of its earnings as a dividend. Dentsply Sirona pays out -13.85% of its earnings as a dividend.

Solventum quarterly revenues are $2.1B, which are larger than Dentsply Sirona quarterly revenues of $879M. Solventum's net income of $137M is higher than Dentsply Sirona's net income of $20M. Notably, Solventum's price-to-earnings ratio is 32.94x while Dentsply Sirona's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Solventum is 1.49x versus 0.90x for Dentsply Sirona. Usually stocks with elevated PS ratios are considered overvalued.